Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10844450 | 0.88 | SLC6A4 (0.46) | PLA2G2ASLC6A4SLC6A3ERN1ALDH1A1 | |
| SCHEMBL27892855 | 0.85 | PLA2G2A (0.45) | PLA2G2ASLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL20295181 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MAPTRAB9APOLBKDM4E | |
| SCHEMBL18373091 | 0.81 | ALDH1A1 (0.55) | ERN1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7014396 | 0.81 | ALDH1A1 (0.55) | ERN1ALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL25106844 | 0.81 | CYP46A1 (0.50) | ERN1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1422117 | 0.81 | ERN1 (0.43) | SLC6A4SLC6A3ERN1ALDH1A1MAPT | |
| SCHEMBL31306269 | 0.80 | ERN1 (0.48) | SLC6A4SLC6A3ERN1ALDH1A1RAB9A | |
| SCHEMBL30301996 | 0.80 | SLC6A4 (0.51) | PLA2G2ASLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL2708451 | 0.80 | SLC6A4 (0.51) | PLA2G2ASLC6A4SLC6A3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748840-A1 | IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF | TAINUORUI (TIANJIN) BIOTECHNOLOGY CO., LTD (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2026-02-05 | — | — | US | disclosed |
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4624466-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-4624472-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| US-12384756-B2 | Piperidinedione derivatives | INNOCURE THERAPEUTICS, INC. (KR) | 2025-08-12 | — | — | US | disclosed |
| WO-2025039774-A1 | IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF | 泰诺瑞(天津)生物科技有限责任公司 | 2025-02-27 | — | — | WO | disclosed |
| CN-118955497-A | Imidazo [1,2-a ] pyridine IRAK4 degradation agent and application thereof | 泰诺瑞(天津)生物科技有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024191988-A1 | 3,4-FUSED BICYCLIC PYRROLIDINE AND 3,4-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS | CYTEIR THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024112120-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112120-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112119-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024112122-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| CN-116323619-A | Piperidinedione derivatives | 因诺库尔治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023009719-A2 | STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS | FOGHORN THERAPEUTICS INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4116298-A1 | PIPERIDINEDIONE DERIVATIVE | Innocure Therapeutics, Inc. (KR) | 2023-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, PSMC1, PSME3 | PLA2G2A 4753/4885SLC6A4 4736/4885SLC6A3 4613/4885 |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, CUL1, PSMB10 | PLA2G2A 4745/4885SLC6A4 4845/4885SLC6A3 4569/4885 |
| US-12384756-B2 | Piperidinedione derivatives | CRBN, CUL1, PSMB10 | PLA2G2A 4745/4885SLC6A4 4845/4885SLC6A3 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.